Frequently Asked Questions for the Illuminating the Druggable Genome Implementation Phase

Updated 4/16/2020

We appreciate your interest in the Illuminating the Druggable Genome Program Request for Application (RFA-RM-20-019) and hope that you and your team will choose to submit an application. In order to maximize your chances of success, we would like to provide some guidance that may be helpful as you put the finishing touches on your application

Overview Questions

1. What is the Common Fund?

2. What is the goal of the Illuminating the Druggable Genome (IDG) Program?

3. What are the experimental approaches being taken in the IDG Program?

R03 Objective Questions

1. What kind of research falls under this FOA?

2. The FOA mentions that applicants are strongly encouraged to use IDG-generated resources either to develop their project or to assist in completing the proposed studies. What does this mean?

3. Can I propose to study proteins that are not on the list in the FOA?

4. Is it acceptable to use an approach that explores more than one protein from the IDG-eligible list?

5. Who is the NIH contact for RFA-RM-20-019 and should I contact them before applying to this FOA?

Application Budget and Submission Requirements

1. R03 project periods are typically 2 years. If I submit an application for $100,000 direct costs to be spent over a two-year period, will NIH accept it?

2. Can an institution/research team submit more than one application to the RFA?

3. Do I need to send a letter of intent?

4. Is collaboration with IDG investigators required to submit an application?

5. Can work be performed outside the US?

6. What are the requirements for data and resource sharing for this FOA?

7. How will applications submitted to RFA-RM-20-019 be reviewed?

This page last reviewed on October 20, 2020